Stay updated on Nivolumab, Tadalafil, Vancomycin in Liver Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab, Tadalafil, Vancomycin in Liver Cancer Clinical Trial page.

Latest updates to the Nivolumab, Tadalafil, Vancomycin in Liver Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedAdded Hepatocellular carcinoma as a study topic and a new Resources link to the Genetic and Rare Diseases Information Center, and updated the site revision to v3.5.0 (replacing v3.4.3).SummaryDifference0.2%

- Check18 days agoChange DetectedSite revision tag updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe study status was updated to Terminated due to poor accrual, with termination dates added and the previous Completed status and completion dates removed.SummaryDifference0.3%

- Check47 days agoChange DetectedRevision: v3.4.2 replaces v3.4.1. No substantive changes to the study details page were detected.SummaryDifference0.0%

- Check54 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1; no changes to the study data or user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check61 days agoChange DetectedThe page now shows a glossary and the 'Last Update Submitted that Met QC Criteria' entry, and includes 'No FEAR Act Data' along with the revision note 'v3.4.0' (replacing 'v3.3.4').SummaryDifference0.2%

Stay in the know with updates to Nivolumab, Tadalafil, Vancomycin in Liver Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab, Tadalafil, Vancomycin in Liver Cancer Clinical Trial page.